(These estimates are based on enrollment in March 2026 and factor in new plans for 2026, plan changes during open enrollment, and new enrollees, and therefore differ from other estimates published in a separate KFF brief, which are based on MedPACs projection of average monthly Part D premiums in 2026 using 2025 enrollment and not factoring in new plans, plan switching, or new enrollees.) The average premium for drug coverage in MA-PDs is heavily weighted by zero-premium plans because MA-PD sponsors can use rebate dollars from Medicare payments to lower or eliminate their Part D premiums
In preclinical studies on tissues like tendons and muscles, significant improvements in healing and function are often observed within a few weeks
Recent animal studies have demonstrated its capacity to enhance cartilage regeneration in osteoarthritis models, suggesting potential therapeutic value for degenerative joint conditions
According to primary care experts, intramuscular shots help quickly restore blood levels of B12 in the body
The 5 mg vial deliberately reconstitutes to the lowest 2.5 mg/mL concentration, which makes the small starting doses easy to measure but pushes larger doses well past a single barrel
